Brexpiprazole: Difference between revisions
From Pharmacopedia
More actions
| [pending revision] | [pending revision] |
Expand Brexpiprazole with Stahl-sourced detail (with skepticism) |
Terminology sweep: drug/medication → medicine |
||
| Line 14: | Line 14: | ||
| pregnancy = Limited data; National Pregnancy Registry available | | pregnancy = Limited data; National Pregnancy Registry available | ||
| legal = Rx | | legal = Rx | ||
| intro = '''Brexpiprazole''' (brand name Rexulti) is a 'pip' D2/5HT1A partial agonist FDA-approved for schizophrenia (2015), adjunctive treatment of major depressive disorder (2015), and — in a landmark 2023 approval — '''agitation associated with Alzheimer dementia'''. It is the first FDA-approved | | intro = '''Brexpiprazole''' (brand name Rexulti) is a 'pip' D2/5HT1A partial agonist FDA-approved for schizophrenia (2015), adjunctive treatment of major depressive disorder (2015), and — in a landmark 2023 approval — '''agitation associated with Alzheimer dementia'''. It is the first FDA-approved medicine specifically for AD agitation. Compared to its 'pip' cousin aripiprazole, brexpiprazole has relatively stronger 5HT2A antagonism, 5HT1A partial agonism, and α1 antagonism — proposed to reduce akathisia and enhance affective/cognitive efficacy. | ||
The AD agitation approval carries the antipsychotic class black-box warning for increased mortality in elderly dementia patients; FDA approval rested on demonstrating a favorable risk-benefit ratio in this population specifically for the indication. | The AD agitation approval carries the antipsychotic class black-box warning for increased mortality in elderly dementia patients; FDA approval rested on demonstrating a favorable risk-benefit ratio in this population specifically for the indication. | ||